NO20076657L - Kombinasjonsterapi av cancer med AZD2171 og gemcitabin - Google Patents

Kombinasjonsterapi av cancer med AZD2171 og gemcitabin

Info

Publication number: NO20076657L
Authority: NO; Norway
Prior art keywords: azd2171; gemcitabine; cancer; human; combination therapy
Prior art date: 2005-07-06

Application number

NO20076657A

Other languages

English (en)

Norwegian (no)

Inventor

Stephen Robert Wedge

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-06

Filing date

2007-12-28

Publication date

2008-04-03

2005-07-06 Priority claimed from GB0513778A external-priority patent/GB0513778D0/en

2005-07-13 Priority claimed from GB0514347A external-priority patent/GB0514347D0/en

2007-12-28 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-04-03 Publication of NO20076657L publication Critical patent/NO20076657L/no

Links

XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 title abstract 6
229960002412 cediranib Drugs 0.000 title abstract 6
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title abstract 6
229960005277 gemcitabine Drugs 0.000 title abstract 6
206010028980 Neoplasm Diseases 0.000 title abstract 4
201000011510 cancer Diseases 0.000 title abstract 3
238000002648 combination therapy Methods 0.000 title 1
241001465754 Metazoa Species 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
230000001772 anti-angiogenic effect Effects 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
230000005865 ionizing radiation Effects 0.000 abstract 2
230000002792 vascular Effects 0.000 abstract 2
239000013066 combination product Substances 0.000 abstract 1
229940127555 combination product Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20076657A 2005-07-06 2007-12-28 Kombinasjonsterapi av cancer med AZD2171 og gemcitabin NO20076657L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0513778A GB0513778D0 (en)	2005-07-06	2005-07-06	Combination therapy
GB0514347A GB0514347D0 (en)	2005-07-13	2005-07-13	Combination therapy
PCT/GB2006/002462 WO2007003933A2 (en)	2005-07-06	2006-07-03	Combination therapy of cancer with azd2171 and gemcitabine

Publications (1)

Publication Number	Publication Date
NO20076657L true NO20076657L (no)	2008-04-03

Family

ID=37005849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20076657A NO20076657L (no)	2005-07-06	2007-12-28	Kombinasjonsterapi av cancer med AZD2171 og gemcitabin

Country Status (12)

Country	Link
US (1)	US20090176731A1 (de)
EP (1)	EP1901754A2 (de)
JP (1)	JP2009500384A (de)
KR (1)	KR20080031029A (de)
AU (1)	AU2006264620B2 (de)
BR (1)	BRPI0612397A2 (de)
CA (1)	CA2614002A1 (de)
IL (1)	IL188513A0 (de)
MX (1)	MX2007016497A (de)
NO (1)	NO20076657L (de)
NZ (1)	NZ564189A (de)
WO (1)	WO2007003933A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0008269D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
GB0223380D0 (en) *	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
BRPI0508959A (pt) *	2004-03-23	2007-08-14	Astrazeneca Ab	uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
GB0406446D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
KR20080077678A (ko) *	2005-12-22	2008-08-25	아스트라제네카 아베	Ａｚｄ2171 및 페메트렉시드의 조합물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0008269D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
GB0223380D0 (en) *	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent
GB0316127D0 (en) *	2003-07-10	2003-08-13	Astrazeneca Ab	Combination therapy
GB0316123D0 (en) *	2003-07-10	2003-08-13	Astrazeneca Ab	Combination therapy
GB0406446D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
BRPI0508959A (pt) *	2004-03-23	2007-08-14	Astrazeneca Ab	uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
CA2569277A1 (en) *	2004-06-04	2005-12-15	Pfizer Products Inc.	Method for treating abnormal cell growth
EP1796672A1 (de) *	2004-09-27	2007-06-20	AstraZeneca AB	Kombinationstherapie gegen krebs mit azd2171 und imatinib
EP1962903B1 (de) *	2005-12-15	2013-03-13	MedImmune Limited	Kombination eines angiopoetin-2-antagonisten und eines vegf-a, kdr- und/oder fltl-antagonisten zur behandlung von krebs
KR20080077678A (ko) *	2005-12-22	2008-08-25	아스트라제네카 아베	Ａｚｄ2171 및 페메트렉시드의 조합물
US20100130519A1 (en) *	2007-04-13	2010-05-27	Stephen Robert Wedge	Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii

2006
- 2006-07-03 EP EP06755701A patent/EP1901754A2/de not_active Withdrawn
- 2006-07-03 BR BRPI0612397-0A patent/BRPI0612397A2/pt not_active Application Discontinuation
- 2006-07-03 MX MX2007016497A patent/MX2007016497A/es not_active Application Discontinuation
- 2006-07-03 WO PCT/GB2006/002462 patent/WO2007003933A2/en not_active Ceased
- 2006-07-03 AU AU2006264620A patent/AU2006264620B2/en not_active Ceased
- 2006-07-03 NZ NZ564189A patent/NZ564189A/en unknown
- 2006-07-03 JP JP2008519988A patent/JP2009500384A/ja active Pending
- 2006-07-03 US US11/994,824 patent/US20090176731A1/en not_active Abandoned
- 2006-07-03 KR KR1020087002092A patent/KR20080031029A/ko not_active Ceased
- 2006-07-03 CA CA002614002A patent/CA2614002A1/en not_active Abandoned
2007
- 2007-12-28 NO NO20076657A patent/NO20076657L/no not_active Application Discontinuation
- 2007-12-31 IL IL188513A patent/IL188513A0/en unknown

Also Published As

Publication number	Publication date
AU2006264620B2 (en)	2009-10-22
KR20080031029A (ko)	2008-04-07
WO2007003933A2 (en)	2007-01-11
WO2007003933A3 (en)	2007-12-27
AU2006264620A1 (en)	2007-01-11
CA2614002A1 (en)	2007-01-11
US20090176731A1 (en)	2009-07-09
JP2009500384A (ja)	2009-01-08
BRPI0612397A2 (pt)	2011-02-22
NZ564189A (en)	2011-04-29
IL188513A0 (en)	2008-08-07
MX2007016497A (es)	2008-03-07
EP1901754A2 (de)	2008-03-26

Legal Events

Date	Code	Title	Description
2013-03-11	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20071428L (no)	2007-04-02	Kombinasjon inneholdende ZD6474 og Imatinib
NO20071426L (no)	2007-06-18	Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20060307L (no)	2006-02-08	Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet
NO20072167L (no)	2007-05-22	Kombinasjon omfattende ZD6474 og et antiandrogen
DK1551409T3 (da)	2007-06-11	Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
NO20050528L (no)	2005-05-03	Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
CY1111547T1 (el)	2015-08-05	Συνδυασμος zd6474 και πεμετρεξεδης
CY1111482T1 (el)	2015-08-05	Συνδυασμος azd2171 και πεμετρεξεδης
NO20056170L (no)	2006-02-08	Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839
NO20064753L (no)	2006-10-20	Kombinasjonsterapi
NO20064755L (no)	2006-10-20	Kombinasjonsterapi
NO20064754L (no)	2006-10-20	Kombinasjonsterapi
WO2007003933A3 (en)	2007-12-27	Combination therapy of cancer with azd2171 and gemcitabine
NO20056171L (no)	2006-02-07	Kombinasjonsterapi
NO20051601L (no)	2005-04-22	Kombinasjonsterapi med gemcitabin og zd6126